GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby ...

Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% during the ...

Scientists have unveiled insights into how HIV-1, the virus responsible for AIDS, skillfully hijacks cellular machinery for its own survival. By dissecting the molecular interplay between the virus ...

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will ...

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, posing a particularly significant threat to people with HIV (PWH). To address this, CVD prevention plans rely on ...

Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...

Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc (SHEL) and Gilead Sciences, Inc. (GILD).

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.